An estimated 370,000 people developed rifampicin-resistant tuberculosis (RR-TB) worldwide in 2025, highlighting the continuing threat of drug-resistant TB, according to the World Health Organization (WHO).The Global Tuberculosis Report 2026 showed a gradual decline in RR-TB since 2015. However, major gaps in diagnosis and treatment persist.Only 155,333 people were diagnosed with RR-TB and started treatment in 2025, just 42% of the estimated number who developed the disease.Drug-resistant TB occurs when bacteria become resistant to one or more medicines. Rifampicin resistance is particularly concerning because rifampicin is a key first-line TB drug.India Among Countries Accounting For Over Half Of Global RR-TB BurdenAlso read: Global TB Deaths Fall 35% Since 2015, But 2030 Target Remains Distant: WHOThe proportion of new TB cases involving rifampicin resistance fell from 4.4% in 2015 to 3.1% in 2025.Resistance remained higher among previously treated patients: 14.8% had RR-TB in 2025, down from 20% in 2015.China, India, the Philippines and the Russian Federation together accounted for more than half of estimated global RR-TB cases in 2025.Eastern Europe and Central Asia reported the highest proportions of RR-TB among previously treated patients, exceeding 50%.India was also among five countries — alongside China, Indonesia, Pakistan and the Philippines — that accounted for about 60% of the global gap between estimated RR-TB cases and people enrolled on treatment.Rifampicin-resistant TB is listed in WHO's Bacterial Priority Pathogens List under the critical group.Why Is Drug-Resistant TB Concerning?WHO identifies two main drivers of multidrug- and rifampicin-resistant TB (MDR/RR-TB): inappropriate treatment and person-to-person transmission.Incorrect use of TB medicines, poor-quality formulations, improper storage and premature treatment stoppage can contribute to drug resistance.Resistant bacteria can also spread between people. Those with pulmonary TB can transmit the infection through coughing, sneezing or talking. Others become infected by inhaling airborne bacteria.Timely diagnosis, appropriate treatment and infection prevention are particularly important in crowded settings such as hospitals and prisons.70% Of Patients With RR-TB Successfully TreatedRead More: 15 Lakh Asymptomatic TB Cases Detected In India: How TB Mukt Bharat Abhiyaan Is Driving ScreeningThe treatment success rate for RR-TB reached 70% among patients who started treatment in 2023, the latest year with available outcome data.This was below the 71% recorded in 2022 but above the rates in 2021 (68%), 2020 (64%) and 2012 (50%).By comparison, treatment success for drug-susceptible TB is about 90%, according to WHO.Across WHO regions, RR-TB treatment success ranged from 56% in the Region of the Americas to 77% in the African Region.Six-Month Treatment Regimens Gain Ground WHO recommends all-oral regimens for drug-resistant TB, including shorter courses for eligible patients. Six-month regimens accounted for 42% of RR-TB treatment in 2025, up from 18% in 2024 and 3% in 2023.By the end of 2025, 106 countries were using these regimens, compared with 98 in 2024 and 60 in 2023.They were the most frequently used treatment option in five of the six WHO regions. Uptake was highest in the Eastern Mediterranean (72%) and African (65%) regions.Europe was the only region where longer regimens remained the main option for a large share of patients (76%).WHO recommends the six-month BPaLM regimen — bedaquiline, pretomanid, linezolid and moxifloxacin — for eligible patients with MDR/RR-TB.Treatment choices depend on drug resistance, previous exposure to TB medicines and other clinical factors.Expanding access to rapid drug-resistance testing, starting treatment promptly and preventing transmission remain key to tackling drug-resistant TB.